Galanin is a neuromodulatory peptide first isolated from porcine intestinal extracts by Tatemoto et al. in 1983, named for its N-terminal glycine and C-terminal alanine residues Tatemoto et al. (1983). Galanin is 29 amino acids in humans (uniquely lacking the C-terminal amidation found in the 30-amino acid form present in most other species) and is widely expressed throughout the central and peripheral nervous systems.

Overview

Galanin is expressed in brain regions of major clinical significance: the locus coeruleus (LC, the principal noradrenergic nucleus), dorsal raphe nucleus (DRN, the principal serotonergic nucleus), basal forebrain cholinergic neurons (including the nucleus basalis of Meynert), hypothalamus, amygdala, hippocampus, and dorsal horn of the spinal cord. In most of these regions, galanin co-localizes with and modulates the release of classical neurotransmitters — it inhibits norepinephrine release in the LC, serotonin release in the DRN, and acetylcholine release in the basal forebrain Hökfelt et al. (2018).

The three galanin receptor subtypes create functional complexity: GalR1 is inhibitory (Gi/o-coupled, hyperpolarizing), GalR2 is predominantly excitatory (Gq/11-coupled, depolarizing, but also couples to Gi/o), and GalR3 is inhibitory (Gi/o-coupled). The net effect of galanin in any given brain region depends on the local expression ratio of these receptor subtypes. This receptor diversity has made galanin pharmacology particularly nuanced — GalR2 agonists are antidepressant and neuroprotective, while GalR1 activation is generally inhibitory and can impair cognition. Understanding subtype-selective pharmacology is central to galanin-based therapeutic development.

Galanin expression is dramatically upregulated following neuronal injury, seizures, and in neurodegenerative disease, suggesting an endogenous neuroprotective role. Galanin is one of the most robustly induced peptides after seizure activity, and galanin knockout mice show increased seizure severity, establishing a clear anticonvulsant function.

Mechanism of Action

Galanin modulates neuronal function through three receptor subtypes with distinct intracellular signaling:

GalR1 (Inhibitory): GalR1 couples to Gi/o proteins, inhibiting adenylyl cyclase, reducing cAMP, and activating G protein-coupled inwardly rectifying potassium (GIRK) channels. GIRK channel activation hyperpolarizes neurons, reducing excitability and neurotransmitter release. GalR1 is highly expressed in the hippocampus (CA1), amygdala, hypothalamus, and spinal cord dorsal horn. In the hippocampus, GalR1 activation inhibits glutamate release and impairs LTP, which may underlie galanin's cognitive-impairing effects at high concentrations.

GalR2 (Excitatory/Trophic): GalR2 primarily couples to Gq/11, activating PLC and generating IP3 and diacylglycerol. IP3-mediated calcium release activates CaMKII, while DAG activates PKC. GalR2 also activates ERK1/2 and Akt survival signaling pathways. Functionally, GalR2 activation is excitatory, neurotrophic, and neuroprotective — promoting neuronal survival, neurite outgrowth, and neurogenesis. GalR2 is expressed in the hippocampal dentate gyrus, amygdala, hypothalamus, and dorsal raphe. GalR2 agonists produce antidepressant-like effects through enhancement of serotonergic and noradrenergic signaling Lu et al. (2007).

GalR3 (Inhibitory): GalR3 couples to Gi/o, inhibiting adenylyl cyclase and activating GIRK channels, similar to GalR1. GalR3 has more restricted expression, with notable presence in the locus coeruleus, raphe nuclei, and hypothalamus. GalR3 antagonists have shown antidepressant-like effects in animal models, suggesting that GalR3 tonically inhibits monoaminergic systems.

Co-transmission Modulation: Galanin is co-stored and co-released with norepinephrine (LC), serotonin (DRN), and acetylcholine (basal forebrain) from the same synaptic vesicles. At low-frequency firing, classical neurotransmitters are preferentially released; at high-frequency firing (as occurs during stress), galanin is co-released and modulates neurotransmitter action through pre- and postsynaptic galanin receptors. This frequency-dependent co-release creates a stress-responsive neuromodulatory system.

Reconstitution Calculator

Research

Safety Profile

Galanin is an endogenous neuropeptide with well-characterized central effects:

• Cognitive effects: Exogenous galanin at supraphysiological doses impairs hippocampus-dependent learning and memory through GalR1-mediated inhibition of cholinergic and glutamatergic transmission. This cognitive-impairing potential is a consideration for non-selective galanin agonist therapies
• Feeding stimulation: Central galanin increases food intake and preferentially drives fat consumption. Weight gain is a theoretical concern for chronic galanin agonist therapy
• Sedation: High-dose ICV galanin produces sedation and reduced locomotor activity, likely through GalR1-mediated inhibition of monoaminergic arousal systems
• Cardiovascular: Galanin produces modest hypotension and bradycardia when administered centrally, through inhibition of sympathetic outflow
• Short half-life: Rapid enzymatic degradation (~6-8 minutes) limits duration of adverse effects with native peptide
• Galanin knockout phenotype: GAL-/- mice show increased anxiety, enhanced pain sensitivity, increased seizure susceptibility, but preserved baseline cognition — confirming galanin's endogenous roles in anxiety regulation, pain modulation, and seizure protection

Clinical Research Protocols

• ICV galanin (preclinical only): 0.1-10 nmol ICV injection for behavioral and neurochemical studies. Not administered centrally in humans.
• Intrathecal galanin (preclinical): 0.1-1 nmol intrathecal injection for spinal pain studies. Human intrathecal studies have not been conducted.
• Galanin CSF measurement: CSF galanin measured by RIA; reference range approximately 20-80 pg/mL. Elevated in Alzheimer's disease and following seizures.
• Genetic studies: GAL, GALR1, GALR2, and GALR3 polymorphism analysis for depression, anxiety, and cognitive trait associations.
• GalR2 agonist development: Preclinical candidates include M1145 and analogs; no GalR2-selective agonist has entered clinical trials as of 2025.

Pharmacokinetic Profile

Ongoing & Future Research

• GalR2-selective agonists for depression: Development of metabolically stable, brain-penetrant GalR2 agonists as a novel antidepressant class targeting a mechanism distinct from monoamine reuptake inhibition.
• GalR1 agonists for epilepsy: Galanin analogs with GalR1 selectivity and improved BBB penetrance for treatment-resistant epilepsy and status epilepticus.
• Galanin in Alzheimer's disease: Investigation of GalR2 agonists to protect cholinergic basal forebrain neurons, potentially slowing progression of cholinergic degeneration.
• GalR3 antagonists for anxiety and addiction: GalR3-selective antagonists for generalized anxiety disorder and alcohol use disorder, building on preclinical evidence of anxiolytic and anti-addiction effects.
• Galanin biomarkers: Development of CSF and plasma galanin as biomarkers for depression treatment response, seizure prediction, and AD staging.
• Galanin in pain medicine: Subtype-selective galanin receptor ligands for neuropathic and inflammatory pain conditions unresponsive to conventional analgesics.